Three-year update of sildenafil citrate (viagra((R))) efficacy and safety

In the three years since its launch, sildenafil citrate (Viagra (R)), an or al agent for the treatment of erectile dysfunction (ED), has been prescribe d to more than 10 million patients worldwide and has been further evaluated in clinical studies in diverse patient populations. Significant improvemen ts in erectile function have been demonstrated in double-blind, placebo-con trolled trials in patients with ED and underlying diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis, Promi sing results have also been reported for patients with treated prostate can cer, end-stage renal failure, Parkinson's disease, and spina bifida and in multiple organ transplant recipients. Accounts of sildenafil use in clinica l practice and postmarketing data reflect clinical trial findings of effect iveness in a broad spectrum of ED aetiologies and overall good tolerability . As in the clinical trials, most adverse events associated with sildenafil use have been transient, mild or moderate effects that rarely lead to trea tment discontinuation.